Erasca Securities Fraud Class Action
Erasca · ERAS-0015 oncology drug candidate · New Filing
About this case
A shareholder class action has been filed against Erasca concerning alleged violations of securities laws involving the company's shares. The matter is at a stage where investors may seek appointment as lead plaintiff; further procedural details are not specified.
Case overview
- Defendant company
- Erasca
- Product or service
- ERAS-0015 oncology drug candidate
- Court case number
- 3:2026cv03481
- Case status
- New Filing
- Lawsuit type
- Securities
- Reported harm
- Misrepresentation
Participation information
Lead Plaintiff Application
Investors who purchased or otherwise acquired Erasca securities during the stated class period may seek appointment as lead plaintiff.
Contact Robbins LLP regarding serving as lead plaintiff. The article states that investors may also remain absent class members by taking no action.
- Type
- Lead Plaintiff
- Reported proof requirement
- Unclear
Erasca Lead Plaintiff Application
Investors are reminded of the opportunity to seek appointment as lead plaintiff in the shareholder class action.
- Type
- Lead Plaintiff
Erasca Investor Legal Consultation
The article invites investors who purchased Erasca shares between January 14, 2025 and April 26, 2026 and experienced an investment loss to contact the law firm regarding their legal rights.
Contact Marshall P. Dees, Esq. by email or telephone, or visit the firm's website for more information.
- Type
- Law Firm Signup
- Reported proof requirement
- Unclear
Sources
- Erasca Securities Fraud Class Action
Eagle-Tribune ·
- Erasca Shareholder Securities Class Action
GlobeNewswire ·
- Erasca Investor Securities Class Action
Benzinga ·
- Erasca Investor Securities Class Action
Barchart.com ·